tiprankstipranks
Atomo Diagnostics Reports Robust Q3 Growth
Company Announcements

Atomo Diagnostics Reports Robust Q3 Growth

Atomo Diagnostics Ltd. (AU:AT1) has released an update.

Don't Miss our Black Friday Offers:

Atomo Diagnostics Ltd.’s Q3 FY24 report shows a significant rise in sales orders, exceeding 520k units for their HIV Self-Test, marking increased global demand and expansion into new markets like Colombia. The company is also advancing in rapid test development with a $3m consortium grant to create a Group Strep B test, contributing to a 25% year-to-date revenue increase. Atomo ends the quarter debt-free, with a strong cash position of $5.2m.

For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App